Population pharmacokinetics analysis of AMG 416, an allosteric activator of the calcium‐sensing receptor, in subjects with secondary hyperparathyroidism receiving hemodialysis

Publisher： John Wiley & Sons Inc

E-ISSN： 1552-4604|55|6|620-628

ISSN： 0091-2700

Source： JOURNAL OF CLINICAL PHARMACOLOGY (ELECTRONIC), Vol.55, Iss.6, 2015-06, pp. : 620-628

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Comparative Effectiveness of Paricalcitol versus Cinacalcet for Secondary Hyperparathyroidism in Patients Receiving Hemodialysis

By  

Nephron Clin Pract, Vol. 117, Iss. 2, 2010-08 ,pp. : c151-c159

Karger

Access to resources Recommend Favorite

THE CALCIUM-SENSING RECEPTOR IN NORMAL PHYSIOLOGY AND PATHOPHYSIOLOGY: A Review

By Tfelt-Hansen Jacob   Brown Edward  

Critical Reviews in Clinical Laboratory Sciences, Vol. 42, Iss. 1, 2004-12 ,pp. : 35-70

Informa Healthcare

Access to resources Recommend Favorite

Association between activating mutations of calcium-sensing receptor and Bartter's syndrome

By Watanabe S.   Fukumoto S.   Chang H.   Takeuchi Y.   Hasegawa Y.   Okazaki R.   Chikatsu N.   Fujita T.  

The Lancet, Vol. 360, Iss. 334, 2002-08 ,pp. : 692-694

Elsevier

Access to resources Recommend Favorite

Comparative cost analysis of management of secondary hyperparathyroidism with paricalcitol or cinacalcet with low-dose vitamin D in hemodialysis patients

By Sharma Amit   Ketteler Markus   Marshall Thomas S.   Khan Samina S.   Schumock Glen T.  

Journal of Medical Economics, Vol. 16, Iss. 9, 2013-09 ,pp. : 1129-1136

Informa Healthcare

Access to resources Recommend Favorite

Vitamin D Receptor and Calcium-Sensing Receptor Gene Polymorphisms in Hypercalciuric Stone-Forming Patients

By  

Nephron Clin Pract, Vol. 114, Iss. 2, 2009-11 ,pp. : c135-c144

Karger

Access to resources Recommend Favorite